ESTRELLA IMMUNOPHARMA, INC. Increase Decrease In Operating Lease Liability
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase Decrease In Operating Lease Liability of $1.53 thousand for the 9-month period ending 2023-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2024-05-15
- ESTRELLA IMMUNOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2023-03-31 was $512.00.
- ESTRELLA IMMUNOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2022-12-31 was $585.00.
- ESTRELLA IMMUNOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2022-09-30 was $430.00.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month |
|---|---|---|---|
| 2023-03-31 | $512.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $1.10K derived: sum of 2 quarters · filed 2024-05-15 | $1.53K 10-Q · filed 2024-05-15 |
| 2022-12-31 | $585.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $1.01K 10-Q · filed 2024-02-14 | |
| 2022-09-30 | $430.00 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |